MX2019014845A - Compuestos de aminotiazol como inhibidores de la proteina quinasa. - Google Patents

Compuestos de aminotiazol como inhibidores de la proteina quinasa.

Info

Publication number
MX2019014845A
MX2019014845A MX2019014845A MX2019014845A MX2019014845A MX 2019014845 A MX2019014845 A MX 2019014845A MX 2019014845 A MX2019014845 A MX 2019014845A MX 2019014845 A MX2019014845 A MX 2019014845A MX 2019014845 A MX2019014845 A MX 2019014845A
Authority
MX
Mexico
Prior art keywords
protein kinase
kinase inhibitors
aminothiazole compounds
compounds
aminothiazole
Prior art date
Application number
MX2019014845A
Other languages
English (en)
Inventor
Chuan Shih
Weir-Torn Jiaang
Hiu-jen TSAI
Original Assignee
Chuan Shih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chuan Shih filed Critical Chuan Shih
Publication of MX2019014845A publication Critical patent/MX2019014845A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos de aminotiazol de la Fórmula (I) que se muestran a continuación y las composiciones farmacéuticas que contienen uno de tales compuestos: (ver Fórmula) También se describen métodos para inhibir una tirosina quinasa y tratar el cáncer asociado con una tirosina quinasa con uno de los compuestos de aminotiazol.
MX2019014845A 2017-06-13 2018-06-13 Compuestos de aminotiazol como inhibidores de la proteina quinasa. MX2019014845A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518855P 2017-06-13 2017-06-13
PCT/US2018/037221 WO2018231910A1 (en) 2017-06-13 2018-06-13 Aminothiazole compounds as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2019014845A true MX2019014845A (es) 2020-08-06

Family

ID=64562741

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014845A MX2019014845A (es) 2017-06-13 2018-06-13 Compuestos de aminotiazol como inhibidores de la proteina quinasa.

Country Status (14)

Country Link
US (1) US10300061B2 (es)
EP (1) EP3638237B1 (es)
JP (1) JP6979595B2 (es)
KR (1) KR102372288B1 (es)
CN (1) CN110831596A (es)
AU (1) AU2018284249B2 (es)
BR (1) BR112019026577A8 (es)
CA (1) CA3064081C (es)
ES (1) ES2949616T3 (es)
MX (1) MX2019014845A (es)
MY (1) MY201291A (es)
TW (1) TWI667236B (es)
WO (1) WO2018231910A1 (es)
ZA (1) ZA202000107B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622966B2 (en) 2018-05-25 2023-04-11 A2A Pharmaceuticals, Inc. Highly potent TACC3 inhibitor as a novel anticancer drug candidate
JP2023517205A (ja) * 2020-03-06 2023-04-24 ナショナル・ヘルス・リサーチ・インスティテューツ ピリミジン化合物及びその薬学的使用
US11299489B1 (en) 2020-11-19 2022-04-12 National Health Research Institutes Thiazole compounds as protein kinase inhibitors
JP2024518711A (ja) * 2021-04-12 2024-05-02 エーツーエー ファーマシューティカルズ インコーポレーテッド 癌を処置するための組成物及び方法
TW202400575A (zh) 2022-03-24 2024-01-01 美商Ａ２Ａ製藥公司 治療癌症的組合物和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507302A (ja) 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド キナーゼ阻害剤
KR20080019578A (ko) * 2005-04-04 2008-03-04 에이비 사이언스 치환된 옥사졸 유도체 및 이의 티로신 키나제 억제제로서의용도
CA2610884A1 (en) 2005-06-09 2006-12-21 Merck & Co., Inc. Inhibitors of checkpoint kinases
GB0610909D0 (en) * 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
JP5563300B2 (ja) * 2006-09-11 2014-07-30 キュリス，インコーポレイテッド 亜鉛結合部分を含むチロシンキナーゼインヒビター
TW200906825A (en) 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
US9255072B2 (en) * 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
KR101924247B1 (ko) * 2011-07-27 2019-02-22 에이비 사이언스 선택적 프로테인 키나제 저해제로서 옥사졸 및 티아졸 유도체
CN106279143A (zh) * 2015-05-11 2017-01-04 天津国际生物医药联合研究院 噻唑杂环类化合物及其制备方法和应用
WO2018106643A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases

Also Published As

Publication number Publication date
BR112019026577A2 (pt) 2020-06-23
KR102372288B1 (ko) 2022-03-08
CA3064081C (en) 2023-03-21
KR20200014350A (ko) 2020-02-10
MY201291A (en) 2024-02-15
CA3064081A1 (en) 2018-12-20
JP2020523348A (ja) 2020-08-06
JP6979595B2 (ja) 2021-12-15
ZA202000107B (en) 2020-12-23
NZ759327A (en) 2021-08-27
CN110831596A (zh) 2020-02-21
WO2018231910A1 (en) 2018-12-20
AU2018284249A1 (en) 2019-12-12
ES2949616T3 (es) 2023-10-02
AU2018284249B2 (en) 2021-06-24
EP3638237A1 (en) 2020-04-22
EP3638237B1 (en) 2023-04-19
TW201906836A (zh) 2019-02-16
TWI667236B (zh) 2019-08-01
US10300061B2 (en) 2019-05-28
US20180353509A1 (en) 2018-12-13
RU2019137573A (ru) 2021-05-24
BR112019026577A8 (pt) 2023-04-11
RU2019137573A3 (es) 2021-07-23
EP3638237A4 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
CR20220066A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
PH12017502203A1 (en) Tyrosine kinase inhibitors
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
MX2019014845A (es) Compuestos de aminotiazol como inhibidores de la proteina quinasa.
MY194262A (en) Inhibitors of ret
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2018006287A (es) Inhibidores de acc de triazol y usos de los mismos.
MX2018006286A (es) Inhibidores de acc pirazolicos y usos de los mismos.
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
EA201691916A1 (ru) Биарильные ингибиторы киназы
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
EA201691549A1 (ru) Ариллактамные ингибиторы киназы
EP3500257A4 (en) KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER